Mark Genovese

USERN Advisory Board

Mark C. Genovese, M.D., is the James W. Raitt Professor of Medicine and Director of the Rheumatology Clinic in the Division of Immunology and Rheumatology at Stanford University Medical Center. He received his bachelor's degree from the University of Notre Dame and his medical degree from the Johns Hopkins University School of Medicine. He completed an internship, residency, and chief residency in the Department of Medicine at Stanford University. He remained at Stanford as a fellow in the Division of Immunology and Rheumatology and subsequently joined the faculty in the same division, serving as the clinic chief. Dr. Genovese has established a clinical research program that is focused on bench-to-bedside translational medicine in autoimmune diseases. He has designed and led numerous investigator-initiated studies and international multi-center trials investigating novel therapies and therapeutic strategies for the treatment of autoimmune disease and arthritis. In addition, he actively collaborates with other investigators on studies of biomarkers, chemokines, cytokines, and cell surface markers associated with disease progression and response to therapy in various autoimmune diseases and arthritis. Dr. Genovese previously served as Director of the Center for Clinical Investigation in the Stanford Department of Medicine. He is an author of over 100 peer review articles, editor on the 7th edition of Kelley’s Textbook of Rheumatology and a board member of the Stanford Clinical Translational Research Unit. He is the recipient of a Center of Immunology at Stanford clinical scholars’ award, the 2008 recipient of the American College of Rheumatology Henry Kunkel award, and is the James W. Raitt Endowed Professor of Medicine at Stanford.

Education:

Fellowship: Stanford University Immunology and Rheumatology Fellowship (1998) CA

Residency: Stanford University Internal Medicine Residency (1996) CA

Residency: Stanford University Internal Medicine Residency (1995) CA

Internship: Stanford University Internal Medicine Residency (1993) CA

Medical Education: Johns Hopkins University School of Medicine (1992) MD

Experience:

Lupus Therapeutics INC Part-time

Board of Directors

Jan 2021 – Present

Kyverna Therapeutics

Board Of Directors

2021 – Present

Gilead Sciences

Senior Vice President Inflammation Development

Apr 2020 – Present

Stanford University

James W. Raitt Endowed Professor of Medicine--Emeritus

Apr 2020 – Present

Professor of Medicine/Immunology/Rheumatology

2008 – Apr 2020

Associate Professor

2004 – 2008

Publications:

A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus

van Vollenhoven, R. F., Park, J. L., Genovese, M. C., West, J. P., & McGuire, J. L. (1999). A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. LUPUS, 8(3), 181–187.
Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity

Kunkel, E. J., Campbell, J. J., Haraldsen, G., Pan, J. L., Boisvert, J., Roberts, A. I., … Agace, W. W. (2000). Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. JOURNAL OF EXPERIMENTAL MEDICINE, 192(5), 761–67.
A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues.

Pan, J., Kunkel, E. J., Gosslar, U., Lazarus, N., Langdon, P., Broadwell, K., … Soler, D. (2000). A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. Journal of Immunology , 165(6), 2943–49.
CCR7 expression and memory T cell diversity in humans Campbell, J. J., Murphy, K. E., Kunkel, E. J., Brightling, C. E., Soler, D., Shen, Z. M., … Wu, L. J. (2001). CCR7 expression and memory T cell diversity in humans. JOURNAL OF IMMUNOLOGY, 166(2), 877–84.
Current management of rheumatoid arthritis Genovese, M. C., & Davis, J. S. (2001). Current management of rheumatoid arthritis. HOSPITAL PRACTICE, 36(2), 21-?
Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential Kim, C. H., Kunkel, E. J., Boisvert, J., Johnston, B., Campbell, J. J., Genovese, M. C., … BUTCHER, E. C. (2001). Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. JOURNAL OF CLINICAL INVESTIGATION, 107(5), 595–601.
Treatment of rheumatoid arthritis with total lymphoid irradiation - Long-term survival Uhrin, Z., Wang, B. W. E., Matsuda, Y., Strober, S., & Genovese, M. C. (2001). Treatment of rheumatoid arthritis with total lymphoid irradiation - Long-term survival. ARTHRITIS AND RHEUMATISM, 44(7), 1525–28.
Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism - By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Robinson, W. H., Genovese, M. C., & Moreland, L. W. (2001). Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism - By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? ARTHRITIS AND RHEUMATISM, 44(9), 1977–1983.
Rules of chemokine receptor association with T cell polarization in vivo Kim, C. H., Rott, L., Kunkel, E. J., Genovese, M. C., Andrew, D. P., Wu, L. J., & BUTCHER, E. C. (2001). Rules of chemokine receptor association with T cell polarization in vivo. JOURNAL OF CLINICAL INVESTIGATION, 108(9), 1331–39.
Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes Kunkel, E. J., Boisvert, J., Murphy, K., Vierra, M. A., Genovese, M. C., Wardlaw, A. J., … Campbell, J. J. (2002). Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. AMERICAN JOURNAL OF PATHOLOGY, 160(1), 347–55.
Autoantigen microarrays for multiplex characterization of autoantibody responses Robinson, W. H., DiGennaro, C., Hueber, W., Haab, B. B., KAMACHI, M., Dean, E. J., … Utz, P. J. (2002). Autoantigen microarrays for multiplex characterization of autoantibody responses. NATURE MEDICINE, 8(3), 295–301.
Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis Genovese, M. C., Uhrin, Z., Bloch, D. A., Oehlert, J., Sibley, R. K., Myers, B., & Strober, S. (2002). Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis. ARTHRITIS AND RHEUMATISM, 46(4), 1014–18.
Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes Genovese, M. C., Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., … Finck, B. K. (2002). Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes. ARTHRITIS AND RHEUMATISM, 46(6), 1443–50.
Central nervous system lupus and pregnancy: 11-year experience at a single center. El-Sayed, Y. Y., Lu, E. J., Genovese, M. C., Lambert, R. E., Chitkara, U., & Druzin, M. L. (2002). Central nervous system lupus and pregnancy: 11-year experience at a single center. Journal of Maternal-Fetal & Neonatal Medicine , 12(2), 99–103.
COX-2 selective NSAID decreases bone ingrowth in vivo Goodman, S., Ma, T., Trindade, M., Ikenoue, T., Matsuura, I., Wong, N., … Smith, R. L. (2002). COX-2 selective NSAID decreases bone ingrowth in vivo. JOURNAL OF ORTHOPAEDIC RESEARCH, 20(6), 1164–69.
Rheumatic syndromes associated with malignancy Chakravarty, E., & Genovese, M. C. (2003). Rheumatic syndromes associated with malignancy. CURRENT OPINION IN RHEUMATOLOGY, 15(1), 35–43.
Allele and antigen-specific treatment of rheumatoid arthritis: A double blind, placebo controlled phase 1 trial Kavanaugh, A., Genovese, M., Baughman, J., Kivitz, A., Bulpitt, K., Olsen, N., … Mocci, S. (2003). Allele and antigen-specific treatment of rheumatoid arthritis: A double blind, placebo controlled phase 1 trial. JOURNAL OF RHEUMATOLOGY, 30(3), 449–54.
Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles. Goodman, S., Trindade, M., Ma, T., Lee, M., Wang, N., Ikenou, T., … Smith, R. L. (2003). Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles. Journal of Biomedical Materials Research. Part A, 65(1), 43–50.
Imaging of the articular cartilage in osteoarthritis of the knee joint: 3D spatial-spectral spoiled gradient-echo vs. fat-suppressed 3D spoiled gradient-echo MR imaging Yoshioka, H., Alley, M., Steines, D., Stevens, K., Rubesova, E., Genovese, M., … Lang, P. (2003). Imaging of the articular cartilage in osteoarthritis of the knee joint: 3D spatial-spectral spoiled gradient-echo vs. fat-suppressed 3D spoiled gradient-echo MR imaging. JOURNAL OF MAGNETIC RESONANCE IMAGING, 18(1), 66–71.
COX-2 selective inhibitors and bone Goodman, S. B., Ma, T., Genovese, M., & Smith, R. L. (2003). COX-2 selective inhibitors and bone. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 16(3), 201–5.
Interleukin 1 receptor antagonist inhibits localized bone formation in vivo Ma, T., Miyanishi, K., Trindade, M. C. D., Genovese, M., Regula, D., Smith, R. L., & Goodman, S. B. (2003). Interleukin 1 receptor antagonist inhibits localized bone formation in vivo. JOURNAL OF RHEUMATOLOGY, 30(12), 2547–52.
A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Genovese, M. C., Chakravarty, E. F., Krishnan, E., & Moreland, L. W. (2004). A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Arthritis Research & Therapy, 6(1), R73–R77.
Unlocking the "PAD" lock on rheumatoid arthritis Utz, P. J., Genovese, M. C., & Robinson, W. H. (2004). Unlocking the "PAD" lock on rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES, 63(4), 330–32.
Articular cartilage of knee: Normal patterns at MR imaging that mimic disease in healthy subjects and patients with osteoarthritis Yoshioka, H., Stevens, K., Genovese, M., Dillingham, M. F., & Lang, P. (2004). Articular cartilage of knee: Normal patterns at MR imaging that mimic disease in healthy subjects and patients with osteoarthritis. RADIOLOGY, 231(1), 31–38.
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate Genovese, M. C., Cohen, S., Moreland, L., Lium, D., Robbins, S., Newmark, R., & Bekker, P. (2004). Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. ARTHRITIS AND RHEUMATISM, 50(5), 1412–19.
Associations between rheumatoid arthritis and malignancy Chakravarty, E. F., & Genovese, M. C. (2004). Associations between rheumatoid arthritis and malignancy. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 30(2), 271-?
Treatment of rheumatoid arthritis with etanercept Genovese, M. C., & Kremer, J. M. (2004). Treatment of rheumatoid arthritis with etanercept. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 30(2), 311-?
Magnetic resonance imaging of articular cartilage of the knee: Comparison between fat-suppressed three-dimensional SPGR imaging, fat-suppressed FSE imaging, and fat-suppressed three-dimensional DEFT imaging, and correlation with arthroscopy Yoshioka, H., Stevens, K., Hargreaves, B. A., Steines, D., Genovese, M., Dillingham, M. F., … Lang, P. (2004). Magnetic resonance imaging of articular cartilage of the knee: Comparison between fat-suppressed three-dimensional SPGR imaging, fat-suppressed FSE imaging, and fat-suppressed three-dimensional DEFT imaging, and correlation with arthroscopy. JOURNAL OF MAGNETIC RESONANCE IMAGING, 20(5), 857–64.
Pharmacologic modulation of periprosthetic osteolysis Goodman, S. B., Trindade, M., Ma, T., Genovese, M., & Smith, R. L. (2005). Pharmacologic modulation of periprosthetic osteolysis. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, (430), 39–45.
Temporal effects of a COX-2-selective NSAID on bone ingrowth. Goodman, S. B., Ma, T., Mitsunaga, L., Miyanishi, K., Genovese, M. C., & Smith, R. L. (2005). Temporal effects of a COX-2-selective NSAID on bone ingrowth. Journal of Biomedical Materials Research. Part A, 72(3), 279–87.
Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus Chakravarty, E. F., Colon, I., Langen, E. S., Nix, D. A., El-Sayed, Y. Y., Genovese, M. C., & Druzin, M. L. (2005). Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 192(6), 1897–1904.
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis Genovese, M. C., Bathon, J. M., Fleischmann, R. M., Moreland, L. W., Martin, R. W., Whitmore, J. B., … Leff, J. A. (2005). Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. JOURNAL OF RHEUMATOLOGY, 32(7), 1232–42.
Antigen microarray profiling of autoantibodies in rheumatoid arthritis Hueber, W., Kidd, B. A., Tomooka, B. H., Lee, B. J., Bruce, B., Fries, J. F., … Robinson, W. H. (2005). Antigen microarray profiling of autoantibodies in rheumatoid arthritis. ARTHRITIS AND RHEUMATISM, 52(9), 2645–55.
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition Genovese, M. C., Becker, J., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., … Dougados, M. (2005). Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. NEW ENGLAND JOURNAL OF MEDICINE, 353(11), 1114–23.
Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis. Magnano, M. D., & Genovese, M. C. (2005). Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis. Current Rheumatology Reports, 7(5), 407–15.
A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis Genovese, M. C., Chakravarty, E. F., Boyle, D. L., Tutuncu, Z., Thorburn, C. M., Halilhodzic, M., … Kavanaugh, A. (2005). A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. JOURNAL OF RHEUMATOLOGY, 32(12), 2345–50.
Biologic therapies in clinical development for the treatment of rheumatoid arthritis Genovese, M. C. (2005). Biologic therapies in clinical development for the treatment of rheumatoid arthritis. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 11(3), S45–S54.
Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines Hueber, W., Tomooka, B. H., Zhao, X., Kidd, B. A., Drijfhout, J. W., Fries, J. F., … Robinson, W. H. (2007). Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. ANNALS OF THE RHEUMATIC DISEASES, 66(6), 712–19.
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis Paniagua, R. T., Sharpe, O., Ho, P. P., Chan, S. M., Chang, A., Higgins, J. P., … Robinson, W. H. (2006). Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. JOURNAL OF CLINICAL INVESTIGATION, 116(10), 2633–42.
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy Genovese, M. C., Mease, P. J., Thomson, G. T. D., Kivitz, A. J., Perdok, R. J., Weinberg, M. A., … Sasso, E. H. (2007). Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. JOURNAL OF RHEUMATOLOGY, 34(5), 1040–50.
A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands Magnano, M. D., Chakravarty, E. F., Broudy, C., Chung, L., Kelman, A., Hillygus, J., & Genovese, M. C. (2007). A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. JOURNAL OF RHEUMATOLOGY, 34(6), 1323–27.
A pilot trial of rituximab in the treatment of patients with dermatomyositis Chung, L., Genovese, M. C., & Fiorentino, D. F. (2007). A pilot trial of rituximab in the treatment of patients with dermatomyositis. ARCHIVES OF DERMATOLOGY, 143(6), 763–67.
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy Genovese, M. C., Schiff, M., Luggen, M., Becker, J.-C., Aranda, R., Teng, J., … Dougados, M. (2008). Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. ANNALS OF THE RHEUMATIC DISEASES, 67(4), 547–54.
Efficacy results from pivotal clinical trials with abatacept Rozelle, A. L., & Genovese, M. C. (2007). Efficacy results from pivotal clinical trials with abatacept. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 25(5), S30–S34.
Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo. Ma, T., Ren, P., Larsen, D. M., Suenaga, E., Zilber, S., Genovese, M., … Goodman, S. B. (2009). Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo. Journal of Biomedical Materials Research. Part A, 89(1), 117–23.
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study Genovese, M. C., Kaine, J. L., Lowenstein, M. B., Del Giudice, J., Baldassare, A., Schechtman, J., … Dummer, W. (2008). Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. ARTHRITIS AND RHEUMATISM, 58(9), 2652–61.
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., … Gomez-Rein, J. J. (2008). Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study. ARTHRITIS AND RHEUMATISM, 58(10), 2968–80.
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients Genovese, M. C., Breedveld, F. C., Emery, P., Cohen, S., Keystone, E., Matteson, E. L., … Shaw, T. M. (2009). Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. ANNALS OF THE RHEUMATIC DISEASES, 68(12), 1894–97.
Inhibition of p38: Has the Fat Lady Sung Genovese, M. C. (2009). Inhibition of p38: Has the Fat Lady Sung. ARTHRITIS AND RHEUMATISM, 60(2), 317–320.
Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis Emery, P., Genovese, M. C., van Vollenhoven, R., Sharp, J. T., Patra, K., & Sasso, E. H. (2009). Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 36(7), 1429–1441.
Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis Hueber, W., Tomooka, B. H., Batliwalla, F., Li, W., Monach, P. A., Tibshirani, R. J., … Robinson, W. H. (2009). Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. ARTHRITIS RESEARCH & THERAPY, 11(3).
First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy Schmajuk, G., & Genovese, M. C. (2009). First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy. JOURNAL OF RHEUMATOLOGY, 36(7), 1559–1560.
LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Genovese, M. C., Van den Bosch, F., ROBERSON, S. A., Bojin, S., Biagini, I. M., Ryan, P., & Sloan-Lancaster, J. (2010). LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study. ARTHRITIS AND RHEUMATISM, 62(4), 929–39.
Abatacept in the Treatment of Patients With Psoriatic Arthritis Mease, P., Genovese, M. C., Gladstein, G., Kivitz, A. J., Ritchlin, C., Tak, P. P., … Gladman, D. (2011). Abatacept in the Treatment of Patients With Psoriatic Arthritis. ARTHRITIS AND RHEUMATISM, 63(4), 939–948.
An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents Genovese, M. C., Kavanaugh, A., Weinblatt, M. E., Peterfy, C., DiCarlo, J., White, M. L., … Magilavy, D. B. (2011). An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents. ARTHRITIS AND RHEUMATISM, 63(2), 337–45.
A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis Genovese, M. C., Cohen, S. B., Wofsy, D., Weinblatt, M. E., Firestein, G. S., Brahn, E., … Tong, S. E. (2011). A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 38(5), 846–54.
Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial Genovese, M. C., Kinnman, N., de La Bourdonnaye, G., Rossi, C. P., & Tak, P. P. (2011). Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial. ARTHRITIS AND RHEUMATISM, 63(7), 1793–1803.
Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate Genovese, M. C., Covarrubias, A., LEON, G., Mysler, E., Keiserman, M., Valente, R., … Alten, R. (2011). Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate. ARTHRITIS AND RHEUMATISM, 63(10), 2854–64.
Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study Genovese, M. C., Han, C., Keystone, E. C., Hsia, E. C., Buchanan, J., Gathany, T., … Rahman, M. U. (2012). Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study. JOURNAL OF RHEUMATOLOGY, 39(6), 1185–91.
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., Mazurov, V., … Mpofu, S. (2013). Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Annals of the Rheumatic Diseases, 72(6), 863–69.
Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy Genovese, M. C., Schiff, M., Luggen, M., Le Bars, M., Aranda, R., Elegbe, A., & DougadoS, M. (2012). Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy. JOURNAL OF RHEUMATOLOGY, 39(8), 1546–54.
Effects of sclerostin antibody on healing of a non-critical size femoral bone defect Jawad, M. U., Fritton, K. E., Ma, T., Ren, P.-G., Goodman, S. B., Ke, H. Z., … Genovese, M. C. (2013). Effects of sclerostin antibody on healing of a non-critical size femoral bone defect. JOURNAL OF ORTHOPAEDIC RESEARCH, 31(1), 155–63.
Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors Genovese, M. C., Fleischmann, R. M., Greenwald, M., Satterwhite, J., Veenhuizen, M., Xie, L., … Benichou, O. (2013). Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. ANNALS OF THE RHEUMATIC DISEASES, 72(9), 1461–68.
Novel small molecule therapeutics in rheumatoid arthritis Kelly, V., & Genovese, M. (2013). Novel small molecule therapeutics in rheumatoid arthritis. RHEUMATOLOGY, 52(7), 1155–62.
Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial Genovese, M. C., Bojin, S., Biagini, I. M., Mociran, E., Cristei, D., Mirea, G., … Sloan-Lancaster, J. (2013). Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial. ARTHRITIS AND RHEUMATISM, 65(4), 880–889.
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Jones, D. A., Musser, T. K., Grossbard, E. B., & Magilavy, D. B. (2013). Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial. JOURNAL OF RHEUMATOLOGY, 40(4), 369–378.
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure Genovese, M. C., Rubbert-Roth, A., Smolen, J. S., Kremer, J., Khraishi, M., Gomez-Reino, J., … van Vollenhoven, R. (2013). Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. JOURNAL OF RHEUMATOLOGY, 40(6), 768–80.
Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Stohl, W., Merrill, J. T., McKay, J. D., Lisse, J. R., Zhong, Z. J., Freimuth, W. W., & Genovese, M. C. (2013). Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study. JOURNAL OF RHEUMATOLOGY, 40(5), 579–589.
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate Genovese, M. C., Lee, E., Satterwhite, J., Veenhuizen, M., Disch, D., Berclaz, P.-Y., … Benichou, O. (2013). A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. ANNALS OF THE RHEUMATIC DISEASES, 72(9), 1453–60.
Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension Keystone, E. C., Genovese, M. C., Hall, S., Miranda, P. C., Bae, S.-C., Palmer, W., … Hsia, E. C. (2013). Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension. JOURNAL OF RHEUMATOLOGY, 40(7), 1097–1103.
Lemierre's syndrome Lee, B. K., LOPEZ, F., Genovese, M., & Loutit, J. S. (1997). Lemierre's syndrome. SOUTHERN MEDICAL JOURNAL, 90(6), 640–43.
Fever, rash, and arthritis in a woman with silicone gel breast implants Genovese, M. C. (1997). Fever, rash, and arthritis in a woman with silicone gel breast implants. WESTERN JOURNAL OF MEDICINE, 167(3), 149–158.
Joint and soft-tissue injection - A useful adjuvant to systemic and local treatment Genovese, M. C. (1998). Joint and soft-tissue injection - A useful adjuvant to systemic and local treatment. POSTGRADUATE MEDICINE, 103(2), 125-?
Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab Breedveld, F. C., Khraishi, M. M., Genovese, M., Emery, P., Moreland, L. W., Keystone, E., … Cooper, S. (2007). Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab. JOURNAL OF RHEUMATOLOGY, 34(7), 1602–1602.
Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab Breedveld, F. C., Van Vollenhoven, R. F., Genovese, M., Emery, P., Moreland, L. W., Keystone, E., … Cooper, S. (2006). Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab. TAYLOR & FRANCIS AS.
Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab Breedveld, F. C., Genovese, M., Emery, P., Moreland, L. W., Keystone, E., Matteson, E. L., … Cooper, S. (2006). Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab. Presented at the Annual European Congress of Rheumatology (EULAR 2006), AMSTERDAM,NETHERLANDS: BMJ PUBLISHING GROUP.
Tofacitinib (CP-690,550) in Combination with Traditional Disease-Modifying Anti-Rheumatic Drugs: Phase 3 Study Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis and An Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs. Strand, V., Kremer, J. M., Li, Z. G., Hall, S., Fleischmann, R. M., Genovese, M. C., … Bradley, J. D. (2011). Tofacitinib (CP-690,550) in Combination with Traditional Disease-Modifying Anti-Rheumatic Drugs: Phase 3 Study Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis and An Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs. ARTHRITIS AND RHEUMATISM, 63(10), S1032–S1032.
A randomized, blinded, parallel group, placebo-controlled, pilot study evaluating the effect of Pvac treatment in patients with diffuse systemic sclerosis Genovese, M. C., Boyle, D., Chakravarty, E., Tutuncu, Z., Thorburn, C., Halilhodzic, M., … Kavanaugh, A. (2004). A randomized, blinded, parallel group, placebo-controlled, pilot study evaluating the effect of Pvac treatment in patients with diffuse systemic sclerosis. ARTHRITIS AND RHEUMATISM, 50(9), S636–S636.
24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. Genovese, M. C., Keystone, E., Taylor, P., Drescher, E., Berclaz, P.-Y., Lee, C. H., … Macias, W. (2012). 24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 64(10), S1049–S1050.
Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. Peterfy, C. G., Emery, P., Genovese, M. C., Keystone, E., Taylor, P., Berclaz, P.-Y., … Macias, W. (2012). Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 64(10), S1050–S1051.
12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis Smolen, J. S., Schlichting, D. E., Sterling, K. L., Keystone, E., Taylor, P., Genovese, M. C., … Gaich, C. L. (2012). 12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 64(10), S214–S214.
24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS Taylor, P., Genovese, M., Keystone, E. C., Drescher, E., Berclaz, P.-Y., Lee, C., … Macias, W. (2013). 24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS. Presented at the Annual Meeting of the British-Society-for-Rheumatology and British-Health-Professionals-in-Rheumatology, BIRMINGHAM,ENGLAND,ENGLAND,ENGLAND: OXFORD UNIV PRESS.
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial Schiff, M., Pritchard, C., Huffstutter, J. E., Rodriguez-Valverde, V., Durez, P., Zhou, X., … Genovese, M. C. (2009). The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. ANNALS OF THE RHEUMATIC DISEASES, 68(11), 1708–1714.
Synovial proteome microarrays identify deiminated proteins as targets of the autoantibody response in Rheumatoid Arthritis Hueber, W., Lee, B. J., Genovese, M. C., Bruce, B., van Venrooij, W. J., Smolen, J. S., … Robinson, W. H. (2003). Synovial proteome microarrays identify deiminated proteins as targets of the autoantibody response in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 48(9), S429–S429.
Multiplex autoantibody profiling using 'synovial proteome' microarrays identifies citrulline-modified peptides as major targets of the autoimmune response in rheumatoid arthritis Hueber, W., Lee, B. J., Genovese, M., van Venrooij, W., Steinman, L., Utz, P. J., & Robinson, W. H. (2003). Multiplex autoantibody profiling using 'synovial proteome' microarrays identifies citrulline-modified peptides as major targets of the autoimmune response in rheumatoid arthritis. Presented at the 3rd World Congress of the Global-Arthritis-Research-Network (GARN), Miyakazi,JAPAN: BIOMED CENTRAL LTD.
Arthritis antigen microarray analysis reveals associations of distinct autoantibody profiles with markers of disease activity and severity in RA. Hueber, W., Kidd, B., Lee, B. J., Genovese, M., Bruce, B., Fries, J., … Robinson, W. H. (2004). Arthritis antigen microarray analysis reveals associations of distinct autoantibody profiles with markers of disease activity and severity in RA. ARTHRITIS AND RHEUMATISM, 50(9), S651–S651.
Fibrinogen-induced arthritis in mice as a novel model for rheumatoid arthritis. Ho, P. P., Tomooka, B. H., Higgins, J. P., Lee, L. Y., Genovese, M., & Robinson, W. H. (2005). Fibrinogen-induced arthritis in mice as a novel model for rheumatoid arthritis. Presented at the 5th Annual Meeting of the Federation-of-Clinical-Immunology-Societies, BOSTON,MA,MA: ACADEMIC PRESS INC ELSEVIER SCIENCE.
Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy: Results from a study in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (reflex) Emery, P., Keystone, E., Peterfy, C. G., Tak, P.-P., Cohen, S. B., Genovese, M. C., … Shaw, T. M. (2008). Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy: Results from a study in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (reflex). Presented at the Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology, LIVERPOOL,ENGLAND,ENGLAND,ENGLAND,ENGLAND,ENGLAND,ENGLAND,ENGLAND: OXFORD UNIV PRESS.
Dehydroepiandrosterone (DHEA) in severe systemic lupus erythematosus. Results of a double-blinded, placebo controlled pilot study. Genovese, M. C., Hendrickson, C. L., Park, J., Powell, M. J., McGuire, J. L., & VANVOLLENHOVEN, R. F. (1997). Dehydroepiandrosterone (DHEA) in severe systemic lupus erythematosus. Results of a double-blinded, placebo controlled pilot study. ARTHRITIS AND RHEUMATISM, 40(9), 168–68.
The impact of disease duration on improvements in ACR responses and remission following abatacept treatment in patients with an inadequate response 2 to anti-TNF therapy in the ATTAIN trial. Genovese, M., Luggen, M., Kremer, J., Sany, J., Aranda, R., Becker, J. C., … Dougados, M. (2005). The impact of disease duration on improvements in ACR responses and remission following abatacept treatment in patients with an inadequate response 2 to anti-TNF therapy in the ATTAIN trial. ARTHRITIS AND RHEUMATISM, 52(9), S137–S137.
Selective co-stimulation modulation with abatacept leads to improvements in ACR responses in patients with an inadequate response to etanercept, infliximab or both: The ATTAIN trial. Dougados, M., Kavanagh, A., Espinoza, L., Sibilia, J., Aranda, R., Becker, J. C., … Luggen, M. (2005). Selective co-stimulation modulation with abatacept leads to improvements in ACR responses in patients with an inadequate response to etanercept, infliximab or both: The ATTAIN trial. ARTHRITIS AND RHEUMATISM, 52(9), S137–S138.
Sustained efficacy along with improvements in disease activity score 28 (DAS 28) and patient (Pt)-reported outcomes (PROs) with abatacept (Aba) in rheumatoid arthritis (RA) pts with an inadequate response to anti-tumor necrosis factor (TNF) therapy: The long-term extension (LTE) of the attain trial Dougados, M., Schiff, M., Luggen, M., Becker, J. C., Aranda, R., Li, T., … Genovese, M. C. (2007). Sustained efficacy along with improvements in disease activity score 28 (DAS 28) and patient (Pt)-reported outcomes (PROs) with abatacept (Aba) in rheumatoid arthritis (RA) pts with an inadequate response to anti-tumor necrosis factor (TNF) therapy: The long-term extension (LTE) of the attain trial. Presented at the Annual Meeting of the British-Society-of-Rheumatology, BIRMINGHAM,ENGLAND,ENGLAND: OXFORD UNIV PRESS.
SAFETY, EFFICACY AND HEALTH-RELATED QUALITY OF LIFE THROUGH 5 YEARS OF ABATACEPT TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO ANTI-TUMOUR NECROSIS FACTOR THERAPY Genovese, M. C., Schiff, M., Luggen, M., Le Bars, M., Becker, J.-C., Aranda, R., … DougadoS, M. (2011). SAFETY, EFFICACY AND HEALTH-RELATED QUALITY OF LIFE THROUGH 5 YEARS OF ABATACEPT TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO ANTI-TUMOUR NECROSIS FACTOR THERAPY. Presented at the Annual Meeting of the British-Society-for-Rheumatology 2011, BRIGHTON,ENGLAND: OXFORD UNIV PRESS.
CTLA4IG (BMS-188667) in a phase IIB, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving etanercept: Association between clinical response and key biomarkers Schiff, M., Genovese, M., Nuamah, I., Becker, J., & Weinblatt, M. (2003). CTLA4IG (BMS-188667) in a phase IIB, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving etanercept: Association between clinical response and key biomarkers. Presented at the Annual European Congress of Rheumatology, LISBON,PORTUGAL: BMJ PUBLISHING GROUP.
Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial. Genovese, M. C., Schiff, M., Luggen, M., Becker, J.-C., Aranda, R., McCann, T., … Dougados, M. (2006). Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial. ARTHRITIS AND RHEUMATISM, 54(9), S244–S244.
Efficacy and safety of abatacept (CTLA41g), a selective co-stimulation modulator, in rheumatoid arthritis patients not responding adequately to anti-TNF-alpha therapy: Results of the phase III ATTAIN (Abatacept trial in treatment of Anti-TNF INadequate responders) Genovese, M., Luggen, M., Schiff, M., Sherrer, Y., Nuamah, I., Aranda, R., … Dougados, M. (2004). Efficacy and safety of abatacept (CTLA41g), a selective co-stimulation modulator, in rheumatoid arthritis patients not responding adequately to anti-TNF-alpha therapy: Results of the phase III ATTAIN (Abatacept trial in treatment of Anti-TNF INadequate responders). ARTHRITIS AND RHEUMATISM, 50(12), 4103–4103.
Efficacy of abatacept following wash-out of anti-TNF therapy in rheumatoid arthritis patients in the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate Responders) trial: Current versus prior discontinuation. Genovese, M., Schiff, M., Luggen, M., Aranda, R., Becker, J. C., White, A., & Dougados, M. (2005). Efficacy of abatacept following wash-out of anti-TNF therapy in rheumatoid arthritis patients in the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate Responders) trial: Current versus prior discontinuation. ARTHRITIS AND RHEUMATISM, 52(9), S560–S561.
Beneficial effects of the selective CO-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatment Emery, R., Westhovens, R., LEON, G., Nuamah, I., Ge, Z., Aranda, R., … Dougados, M. (2005). Beneficial effects of the selective CO-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatment. Presented at the Annual European Congress of Rheumatology, VIENNA,AUSTRIA: BMJ PUBL

No items yet!